Researches on drug delivery system (DDS) have made incredible progress, but there are still problems such as insufficient targeting and undesirable treatment efficiency. To improve the above problems, a stem cell-based DDS was developed. Stem cell and its derivatives (cell membranes, extracellular vesicles/exosomes) have been used as important drug delivery vehicles in the treatment of a number of human key diseases, such as genetic diseases, cancer and so on. For stem cells highly express chemokine receptors such as CCR2 and CXCR4, which can specifically bind to chemokines or cytokines produced in tissue injury sites, so they exhibit centripetal and homing properties, which is the reason why they are employed as DDS vehicles. Stem cell-based DDS effectively enhance the targeting and efficiency of drugs with low immunogenicity. We review the extremely prominent superiority of stem cells and its derivatives as drug delivery vehicles. Especially summarize the different targeting strategies and the major application in anti-tumor, anti-inflammatory, tissue repair and regenerative medicine fields. The challenges of stem cell-based targeted DDS are still how to enhance their targeting, selectivity, effectiveness, reducing immunogenicity, and fully exerting its immunomodulatory effects. We think stem cell and its derivatives-based DDS will demonstrate their significant prospects in the future.

药物递送系统（DDS）的研究取得了令人难以置信的进展，但仍存在靶向性不足、治疗效率不理想等问题。为了改善上述问题，开发了基于干细胞的 DDS。干细胞及其衍生物（细胞膜、细胞外囊泡/外泌体）已被用作重要的药物递送载体，用于治疗许多人类关键疾病，如遗传疾病、癌症等。由于干细胞高表达趋化因子受体，如CCR2和CXCR4，它们可以与组织损伤部位产生的趋化因子或细胞因子特异性结合，因此它们表现出向心和归巢特性，这就是它们被用作DDS载体的原因。基于干细胞的DDS有效地增强了低免疫原性药物的靶向性和效率。我们回顾了干细胞及其衍生物作为药物输送载体的极其突出的优势。特别总结了不同的靶向策略及其在抗肿瘤、抗炎、组织修复和再生医学领域的主要应用。基于干细胞的靶向DDS的挑战仍然是如何增强其靶向性、选择性、有效性，降低免疫原性，并充分发挥其免疫调节作用。我们认为干细胞及其衍生的 DDS 将在未来展示其重要的前景。基于干细胞的靶向DDS的挑战仍然是如何增强其靶向性、选择性、有效性，降低免疫原性，并充分发挥其免疫调节作用。我们认为干细胞及其衍生的 DDS 将在未来展示其重要的前景。基于干细胞的靶向DDS的挑战仍然是如何增强其靶向性、选择性、有效性，降低免疫原性，并充分发挥其免疫调节作用。我们认为干细胞及其衍生的 DDS 将在未来展示其重要的前景。